- Encouraging progress supports near-term focus on lead wholly-owned program, CX-2051 (EpCAM PROBODY ® ADC). Initial Phase 1a clinical data in advanced metastatic colorectal cancer (CRC) are anticipated in the first half of 2025 - - Early-stage research and platform capabilities to be concentrated